Title | Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, Pring J, Pack M, Buckley N, Matei I, Lyden D, Green J, Hawthorne T, Marsh HC, Yellin M, Davis T, Keler T, Schlesinger SJ |
Journal | Bone Marrow Transplant |
Volume | 50 |
Issue | 7 |
Pagination | 924-30 |
Date Published | 2015 Jul |
ISSN | 1476-5365 |
Keywords | Adolescent, Adult, Dendritic Cells, Female, fms-Like Tyrosine Kinase 3, Healthy Volunteers, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Transplantation Conditioning, Young Adult |
Abstract | Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripheral blood and lymphoid organs. CDX-301 has an identical amino-acid sequence and comparable biological activity to the previously tested rhuFlt3L, which ceased clinical development over a decade ago. This Phase 1 trial assessed the safety, pharmacokinetic, pharmacodynamic and immunologic profile of CDX-301, explored alternate dosing regimens and examined the impact of rhuFlt3L on key immune cell subsets. Thirty healthy volunteers received CDX-301 (1-75 μg/kg/day) over 5-10 days. One event of Grade 3 community-acquired pneumonia occurred. There were no other infections, dose-limiting toxicities or serious adverse events. CDX-301 resulted in effective peripheral expansion of monocytes, hematopoietic stem and progenitor cells and key subsets of myeloid DCs and plasmacytoid DCs, with no clear effect on regulatory T cells. These data from healthy volunteers support the potential for CDX-301, as monotherapy or in combination with other agents, in various indications including allogeneic HSC transplantation and immunotherapy, but the effects of CDX-301 will need to be investigated in each of these patient populations. |
DOI | 10.1038/bmt.2015.74 |
Custom 1 | |
Alternate Journal | Bone Marrow Transplant. |
PubMed ID | 25915810 |
PubMed Central ID | PMC4532305 |
Grant List | KL2 TR000151 / TR / NCATS NIH HHS / United States UL1 TR000043 / TR / NCATS NIH HHS / United States K23 AR063461 / AR / NIAMS NIH HHS / United States UL1TR000043/KL2TR000151 / TR / NCATS NIH HHS / United States AR063461-01A1 / AR / NIAMS NIH HHS / United States U19AI111825 / AI / NIAID NIH HHS / United States U19 AI111825 / AI / NIAID NIH HHS / United States |